Compare KMX & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMX | ALKS |
|---|---|---|
| Founded | 1993 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.5B |
| IPO Year | 2002 | 2012 |
| Metric | KMX | ALKS |
|---|---|---|
| Price | $42.31 | $27.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 14 |
| Target Price | $40.08 | ★ $43.43 |
| AVG Volume (30 Days) | ★ 2.9M | 1.8M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.29 | N/A |
| EPS | ★ 2.46 | 1.43 |
| Revenue | ★ $26,353,420,000.00 | $1,475,899,000.00 |
| Revenue This Year | N/A | $24.06 |
| Revenue Next Year | $0.73 | $4.53 |
| P/E Ratio | ★ $17.21 | $19.37 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.40 | $25.17 |
| 52 Week High | $82.79 | $36.32 |
| Indicator | KMX | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 28.80 |
| Support Level | $39.57 | $25.65 |
| Resistance Level | $42.64 | $28.75 |
| Average True Range (ATR) | 1.60 | 0.87 |
| MACD | 0.06 | -0.16 |
| Stochastic Oscillator | 72.23 | 6.73 |
CarMax sells, finances, and services used and new cars through a chain of over 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 83% of fiscal 2025 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2025, the company retailed and wholesaled 789,050 and 544,312 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in calendar 2024. It seeks over 5% share. CarMax is based in Richmond, Virginia.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.